Conference Call Participants
Subhalaxmi Nambi – Guggenheim Securities, LLC, Research Division
Richard Vosser – JPMorgan Chase & Co, Research Division
Douglas Schenkel – Wolfe Research, LLC
Harry Sephton – UBS Investment Bank, Research Division
James Quigley – Goldman Sachs Group, Inc., Research Division
Charles Pitman – Barclays Bank PLC, Research Division
Charlie Haywood – BofA Securities, Research Division
James Vane-Tempest – Jefferies LLC, Research Division
Charles Weston – RBC Capital Markets, Research Division
Odysseas Manesiotis – BNP Paribas, Research Division
Thibault Boutherin – Morgan Stanley, Research Division
Oliver Metzger – ODDO BHF Corporate & Markets, Research Division
Falko Friedrichs – Deutsche Bank AG, Research Division
Harry Gillis – Joh. Berenberg, Gossler & Co. KG, Research Division
Shubhangi Gupta – HSBC Global Investment Research
Anna Snopkowski – KeyBanc Capital Markets Inc., Research Division
Naresh Chouhan – Intron Health Advisors Ltd
Delphine Le Louet – Bernstein Institutional Services LLC, Research Division
Presentation
Operator
Welcome to the presentation of Sartorius and Sartorius Stedim Biotech on the Preliminary Results 2025. Please note that the call is being recorded and streamed on Sartorius’ website. Your participation in this implies your consent with this. A replay will be available shortly after the call.
I would now like to turn the conference over to Petra Müller, Head of Investor Relations of Sartorius.
Petra Muller
Head of Investor Relations
Thank you, operator. Hello, and a warm welcome from my side. I’m joined today by our CEO, Michael Grosse; by Florian Funck, our CFO; by René Fáber, Head of our Bioprocessing Division and CEO of Sartorius Stedim Biotech; and by Alexandra Gatzemeyer, Head of our Lab Products & Services division. As always, we will start with prepared remarks followed by the Q&A session.
